Trials / Unknown
UnknownNCT04252274
Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Shanghai Public Health Clinical Center · Other Government
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The study aims to evaluate the efficacy and safety of darunavir and cobistastat in the treatment of COVID-19 pneumonia
Detailed description
There is no vaccine or antiviral treatment for human coronavirus, so this study aims to evaluate the efficacy and safety of darunavir and cobistastat in the treatment of COVID-19 pneumonia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Darunavir and Cobicistat | Subjects take darunavir and cobicistat one tablet per day for 5 days, also take conventional treatments |
Timeline
- Start date
- 2020-01-30
- Primary completion
- 2020-08-31
- Completion
- 2020-12-31
- First posted
- 2020-02-05
- Last updated
- 2020-04-13
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04252274. Inclusion in this directory is not an endorsement.